CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
citicoline +1 moredrug
Likely dose
Citicoline 2 gm/day orally for 8 weeksAI-extracted
Key inclusion· 3
  • Meets DSM-IV criteria for current marijuana dependence
  • Heavy smoker, defined as smoking more than 10 joints per week
  • Women must have negative pregnancy test prior to study entry
Key exclusion· 9
  • Abnormal electrocardiogram (ECG)
  • Medical disorder that requires prescription medication
  • Psychiatric disorder that requires prescription medication
  • Abnormal liver function tests

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00158249
NCT00158249Phase 2Completed

Cannabis Dependence: Imaging and Medication Development - 1

Mclean Hospital·interventional·Posted Sep 12, 2005·Updated Oct 22, 2014

In Brief

A Phase 2 clinical trial evaluating citicoline and placebo for Marijuana Abuse. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The Three Aims of this study are (only studies for Aim 1 were completed) 1. Measure the impact of citicoline on marihuana use patterns in subjects' individualized natural settings and responses to marihuana challenge using functional brain MRI scans. Hypothesis - 2 g/day citicoline will produce greater reductions in marihuana use and craving in heavy marihuana users than placebo citicoline over a 8-week treatment period as measured in their natural environments. The same participants will experience greater improved brain activation patterns and an improvement in cognitive functioning compared to placebo controlled subjects. 2. Measure the effects of citicoline on marihuana absorption and metabolism and determine if these changes parallel changes in subjective and physiological responses in a laboratory setting. Hypothesis - Chronic (8 weeks) treatment with 2 g/day citicoline will produce increases in subjective and physiological effects of both acute marihuana smoking and placebo marihuana smoking compared to chronic placebo citicoline. Citicoline will have no effect on marihuana pharmacokinetics. 3. Measure the effects of citicoline on marijuana-induced cue-induced craving and brain electrical activity (EEG). Hypothesis - Chronic (8 weeks) treatment with 2 g/day citicoline will reduce objective measures of marijuana cue-reactivity, and subjective reports of craving in response to marihuana cues will also be attenuated compared to chronic placebo citicoline treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarijuana Abuse
CountriesUnited States

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2005
Enrollment StartSep 1, 2009
Primary CompletionJan 1, 2013
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.8 years ago

Interventions

citicolinedrug

2 gm/day, 8 weeks treatment

placebodrug

matched for physical appearance